Portal Biotechnologies Raises $9 Million

Portal Biotechnologies has announced a successful funding round, securing $9 million in an oversubscribed investment led by NFX. Additional participants in this round included IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU Ventures. The company specializes in a unique approach to cell engineering, focusing on delivering complex molecules into cells without the traditional transfection methods.

What Portal Biotechnologies Does

Co-founded by Alec Barclay, who serves as the Chief Operating Officer, and led by CEO Armon Sharei, PhD, Portal Biotechnologies offers a platform that leverages mechanoporation. This technology facilitates the efficient and scalable delivery of RNA, gene editors, and other molecules into hard-to-transfect cells, which is a significant challenge in the fields of drug discovery and cell therapy.

Strategic Use of Funds

The newly acquired capital is earmarked for the commercial scaling of Portal's platform. The company is focusing its expansion on three key areas:

  • Novel Drug Discovery Workflows: Enhancing the processes for discovering new drugs and therapies.
  • Cost-effective Multi-perturbation AI Data Generation: Generating data that can be used to train AI models more efficiently.
  • Next-generation Cell Therapies: Collaborating with academic and biopharma partners to advance cell therapies.

Portal has already made significant strides, boasting over 100 customers, including prominent organizations such as Microsoft, Merck, AbbVie, Mass General Brigham, Ragon Institute, and Purdue University. These collaborations highlight the technology’s application in various complex assays and screening methods.

Notable Collaborations and Projects

Portal Biotechnologies is actively engaged in several high-profile projects. A collaboration with the Ragon Institute of Harvard, MIT, and Mass General Brigham, alongside Microsoft, aims to utilize the platform for large-scale immune response mapping. Additionally, DARPA has expanded its $8 million contract with Portal, supporting the development of a portable device for rapid cell therapy production.

Future Developments

The funding will also support further collaborations in multi-perturbation screens, enhancing the company’s capabilities in cell therapy production. Portal’s platform is already seeing upgrades, with multiple pharmaceutical clients transitioning to its high-throughput Galaxy-i platform.

With this significant investment, Portal Biotechnologies is well-positioned to continue its growth and innovation in the cell engineering sector, paving the way for advancements in drug discovery and therapy development.